HMGCR loss is synthetic lethal with PIK3CD inhibition in colorectal cancer cells

Figure 3 Atorvastatin combined with gefitinib inhibited the AMPK-SREBP1 signaling pathway. A and B: Western blotting analysis revealed that, after combination treatment with atorvastatin and gefitinib, the expression of p-AMPK and SREBP1 decreased compared with that in the single-agent atorvastatin or gefitinib groups; C and D: Western blotting analysis revealed that, after combination treatment with sh-HMGCR and gefitinib, the expression of p-AMPK and SREBP1 decreased compared with that in the single-agent sh-HMGCR or gefitinib groups. Data are presented as the mean ± SD. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001.